Risk of second malignant neoplasms after cyclophosphamide-based chemotherapy with or without radiotherapy for non-Hodgkin lymphoma

Yuanlin Xu, Huaqing Wang, Shiyong Zhou, Man Yu, Xianhuo Wang, Kai Fu, Zhengzi Qian, Huilai Zhang, Lihua Qiu, Xianming Liu, Ping Wang

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Relatively little information is available on quantitative risks of therapy-induced second malignant neoplasm (SMN) in patients with non-Hodgkin lymphoma (NHL). A nested case-control study was conducted in a cohort of 3412 patients treated for NHL between 1990 and 2006, including 118 patients with SMN and 472 controls. Risks of leukemia/lung/breast/colorectal and bladder cancer were higher in NHL compared with the general population. A higher risk of leukemia was restricted to patients given a cumulative dose of cyclophosphamide more than 11 250 mg/m2. However, no significant association was found between SMN risk with rituximab, fludarabine, anthracyclines, epipodophyllotoxins and platinum, respectively. In combined modality treatment, involved-eld radiation therapy (IFRT) had a higher risk for second solid cancers as compared to involved-nodal radiation therapy (INRT). For patients receiving radiation doses exceeding 40 Gy, the risk of lung cancer and breast cancer was increased. In conclusion, we found that cyclophosphamide-based therapy increased the risk of SMN in NHL. Leukemia risk was linked with high-dose cyclophosphamide. A received larger radiation field or higher radiation dose also could be an important risk factor for the development of SMN.

Original languageEnglish (US)
Pages (from-to)1396-1404
Number of pages9
JournalLeukemia and Lymphoma
Volume54
Issue number7
DOIs
StatePublished - Jul 1 2013

Fingerprint

Second Primary Neoplasms
Non-Hodgkin's Lymphoma
Cyclophosphamide
Radiotherapy
Drug Therapy
Leukemia
Radiation
Breast Neoplasms
Podophyllotoxin
Anthracyclines
Platinum
Urinary Bladder Neoplasms
Case-Control Studies
Colorectal Neoplasms
Lung Neoplasms
Therapeutics
Lung

Keywords

  • Chemotherapy
  • Non-Hodgkin lymphoma
  • Radiotherapy
  • Risk factors
  • Second malignant neoplasm

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Risk of second malignant neoplasms after cyclophosphamide-based chemotherapy with or without radiotherapy for non-Hodgkin lymphoma. / Xu, Yuanlin; Wang, Huaqing; Zhou, Shiyong; Yu, Man; Wang, Xianhuo; Fu, Kai; Qian, Zhengzi; Zhang, Huilai; Qiu, Lihua; Liu, Xianming; Wang, Ping.

In: Leukemia and Lymphoma, Vol. 54, No. 7, 01.07.2013, p. 1396-1404.

Research output: Contribution to journalArticle

Xu, Yuanlin ; Wang, Huaqing ; Zhou, Shiyong ; Yu, Man ; Wang, Xianhuo ; Fu, Kai ; Qian, Zhengzi ; Zhang, Huilai ; Qiu, Lihua ; Liu, Xianming ; Wang, Ping. / Risk of second malignant neoplasms after cyclophosphamide-based chemotherapy with or without radiotherapy for non-Hodgkin lymphoma. In: Leukemia and Lymphoma. 2013 ; Vol. 54, No. 7. pp. 1396-1404.
@article{fcd1006522ed4ace9e17601cbc41afcf,
title = "Risk of second malignant neoplasms after cyclophosphamide-based chemotherapy with or without radiotherapy for non-Hodgkin lymphoma",
abstract = "Relatively little information is available on quantitative risks of therapy-induced second malignant neoplasm (SMN) in patients with non-Hodgkin lymphoma (NHL). A nested case-control study was conducted in a cohort of 3412 patients treated for NHL between 1990 and 2006, including 118 patients with SMN and 472 controls. Risks of leukemia/lung/breast/colorectal and bladder cancer were higher in NHL compared with the general population. A higher risk of leukemia was restricted to patients given a cumulative dose of cyclophosphamide more than 11 250 mg/m2. However, no significant association was found between SMN risk with rituximab, fludarabine, anthracyclines, epipodophyllotoxins and platinum, respectively. In combined modality treatment, involved-eld radiation therapy (IFRT) had a higher risk for second solid cancers as compared to involved-nodal radiation therapy (INRT). For patients receiving radiation doses exceeding 40 Gy, the risk of lung cancer and breast cancer was increased. In conclusion, we found that cyclophosphamide-based therapy increased the risk of SMN in NHL. Leukemia risk was linked with high-dose cyclophosphamide. A received larger radiation field or higher radiation dose also could be an important risk factor for the development of SMN.",
keywords = "Chemotherapy, Non-Hodgkin lymphoma, Radiotherapy, Risk factors, Second malignant neoplasm",
author = "Yuanlin Xu and Huaqing Wang and Shiyong Zhou and Man Yu and Xianhuo Wang and Kai Fu and Zhengzi Qian and Huilai Zhang and Lihua Qiu and Xianming Liu and Ping Wang",
year = "2013",
month = "7",
day = "1",
doi = "10.3109/10428194.2012.743657",
language = "English (US)",
volume = "54",
pages = "1396--1404",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Risk of second malignant neoplasms after cyclophosphamide-based chemotherapy with or without radiotherapy for non-Hodgkin lymphoma

AU - Xu, Yuanlin

AU - Wang, Huaqing

AU - Zhou, Shiyong

AU - Yu, Man

AU - Wang, Xianhuo

AU - Fu, Kai

AU - Qian, Zhengzi

AU - Zhang, Huilai

AU - Qiu, Lihua

AU - Liu, Xianming

AU - Wang, Ping

PY - 2013/7/1

Y1 - 2013/7/1

N2 - Relatively little information is available on quantitative risks of therapy-induced second malignant neoplasm (SMN) in patients with non-Hodgkin lymphoma (NHL). A nested case-control study was conducted in a cohort of 3412 patients treated for NHL between 1990 and 2006, including 118 patients with SMN and 472 controls. Risks of leukemia/lung/breast/colorectal and bladder cancer were higher in NHL compared with the general population. A higher risk of leukemia was restricted to patients given a cumulative dose of cyclophosphamide more than 11 250 mg/m2. However, no significant association was found between SMN risk with rituximab, fludarabine, anthracyclines, epipodophyllotoxins and platinum, respectively. In combined modality treatment, involved-eld radiation therapy (IFRT) had a higher risk for second solid cancers as compared to involved-nodal radiation therapy (INRT). For patients receiving radiation doses exceeding 40 Gy, the risk of lung cancer and breast cancer was increased. In conclusion, we found that cyclophosphamide-based therapy increased the risk of SMN in NHL. Leukemia risk was linked with high-dose cyclophosphamide. A received larger radiation field or higher radiation dose also could be an important risk factor for the development of SMN.

AB - Relatively little information is available on quantitative risks of therapy-induced second malignant neoplasm (SMN) in patients with non-Hodgkin lymphoma (NHL). A nested case-control study was conducted in a cohort of 3412 patients treated for NHL between 1990 and 2006, including 118 patients with SMN and 472 controls. Risks of leukemia/lung/breast/colorectal and bladder cancer were higher in NHL compared with the general population. A higher risk of leukemia was restricted to patients given a cumulative dose of cyclophosphamide more than 11 250 mg/m2. However, no significant association was found between SMN risk with rituximab, fludarabine, anthracyclines, epipodophyllotoxins and platinum, respectively. In combined modality treatment, involved-eld radiation therapy (IFRT) had a higher risk for second solid cancers as compared to involved-nodal radiation therapy (INRT). For patients receiving radiation doses exceeding 40 Gy, the risk of lung cancer and breast cancer was increased. In conclusion, we found that cyclophosphamide-based therapy increased the risk of SMN in NHL. Leukemia risk was linked with high-dose cyclophosphamide. A received larger radiation field or higher radiation dose also could be an important risk factor for the development of SMN.

KW - Chemotherapy

KW - Non-Hodgkin lymphoma

KW - Radiotherapy

KW - Risk factors

KW - Second malignant neoplasm

UR - http://www.scopus.com/inward/record.url?scp=84879335946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879335946&partnerID=8YFLogxK

U2 - 10.3109/10428194.2012.743657

DO - 10.3109/10428194.2012.743657

M3 - Article

VL - 54

SP - 1396

EP - 1404

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 7

ER -